Palvella Therapeutics has moved its lead drug candidate, QTORIN 3.9% rapamycin gel, into an expedited FDA review for microcystic lymphatic malformations, a rare and debilitating condition with no currently approved treatment in the U.S. The agency set a target decision date of Feb. 28, 2027.
The decision brings Palvella closer to a potential first product launch. The company says it is preparing to market the treatment on its own in the U.S. in the first half of 2027, if the FDA approves it.
Key details
- Priority Review and timing: The FDA accepted Palvella’s application for review and granted Priority Review. The Feb. 28, 2027, target date is when the agency aims to act on the application; it is not an approval.
- Clinical evidence: The application is supported by the Phase 3 SELVA study, which met all six prespecified efficacy endpoints, with each result statistically significant at p<0.001. Among participants aged 6 and older who completed the efficacy evaluation period, 95% showed improvement on the study’s primary measure.
- Safety findings: Palvella reported that QTORIN was well tolerated in SELVA, with no drug-related serious adverse events. Measured systemic rapamycin concentrations remained below 2 ng/mL at all measured timepoints for all participants.
- Other supporting evidence: The application also includes Phase 2 results, published literature and other evidence on rapamycin use for the condition. Phase 2 results supported the FDA’s earlier decision to grant the drug Breakthrough Therapy designation.
- Additional FDA designations: QTORIN has also received Fast Track and Orphan Drug designations for microcystic lymphatic malformations. The development program has received grant funding from the FDA’s Office of Orphan Products Development.
- The condition: Microcystic lymphatic malformations are persistent and can cause leaking, bleeding, recurrent infections and functional impairment. Palvella estimates that more than 30,000 people in the U.S. are diagnosed with the condition. Existing procedures can be limited by recurrence and the need for repeat treatment; there are no FDA-approved therapies.
- Launch preparation: Palvella is preparing for a potential standalone U.S. launch in the first half of 2027. It says it has rare-disease commercial leadership, a nationwide medical science liaison team and patient services capabilities, and is working on disease education, specialist engagement, patient identification, market access and patient support.
- Other programs: The company is also developing QTORIN rapamycin for cutaneous venous malformations and clinically significant angiokeratomas, and QTORIN pitavastatin for disseminated superficial actinic porokeratosis.
If approved, QTORIN would be Palvella’s first marketed product and the first FDA-approved therapy for microcystic lymphatic malformations, marking a shift from clinical-stage development toward commercial operations.